Indivior Plc

Indivior Plc

INDV

Get informed when a big investor buys or sells

+ Follow
Market Cap$4.35B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Indivior PlcIndivior Plc12.3--175%3.5-0.4
$47.33

Target Price by Analysts

35% upsideIndivior Plc Target Price DetailsTarget Price
$-1.25

Current Fair Value

103.6% downside

Overvalued by 103.6% based on the discounted cash flow analysis.

Share Statistics

Market cap$4.35 Billion
Enterprise Value$4.24 Billion
Dividend Yield$- (-)
Earnings per Share$1.68
Beta1.03
Outstanding Shares125,352,000

Return

Return on Equity-175.00%ROE
Return on Assets21.05%
Return on Invested Capital81.10%

Valuation & Multiples

P/E Ratio12.28P/E Ratio
PEG13.74PEG
Price to Sales3.51Price to Sales
Price to Book Ratio-17.53Price to Book Ratio
Enterprise Value to Revenue3.29
Enterprise Value to EBIT12.5
Enterprise Value to Net Income16
Total Debt to Enterprise0.01
Debt to Equity-0.44Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 4, 2026
EPS Estimate
$0.89
Average shareholder expectation
Revenue Estimate
$307.55 M
Average shareholder expectation

Next Earnings Call

Expected Date
October 29, 2026
EPS Estimate
$1.06
Average shareholder expectation
Revenue Estimate
$329.35 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.3684 50.46%
Total Calls2,401,500 672.43%
Total Puts884,600 225.94%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %101.65% 0.53%
Total Invested$5.14B 32.20%
Investors Holding347 51.00%

ESG Score

No data

About Indivior Plc

CEO: Shaun Thaxter

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, Subutex Tablet, ...